These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17931455)

  • 21. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
    Tam DH; Farber HW
    Am J Hematol; 2006 Jun; 81(6):443-7. PubMed ID: 16680745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.
    De Sanctis V; Pinamonti A; Di Palma A; Sprocati M; Atti G; Gamberini MR; Vullo C
    Eur J Pediatr; 1996 May; 155(5):368-72. PubMed ID: 8741032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.
    Styles LA; Vichinsky EP
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):42-5. PubMed ID: 8556369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.
    Levine JE; Cohen A; MacQueen M; Martin M; Giardina PJ
    J Pediatr Hematol Oncol; 1997; 19(2):139-41. PubMed ID: 9149744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can deferoxamine be considered an ototoxic drug?
    Masala W; Meloni F; Gallisai D; Careddu M; Secchi G; Cuccuru GB; Loriga V; Salvo G
    Scand Audiol Suppl; 1988; 30():237-8. PubMed ID: 3227279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.
    Chan YL; Pang LM; Chik KW; Cheng JC; Li CK
    Pediatr Radiol; 2002 Jul; 32(7):492-7. PubMed ID: 12107582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran.
    Sadeghi-Bojd S; Hashemi M; Karimi M
    Singapore Med J; 2008 May; 49(5):410-2. PubMed ID: 18465053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
    Cases A; Kelly J; Sabater J; Campistol JM; Torras A; Montoliu J; López I; Revert L
    Clin Nephrol; 1988 Apr; 29(4):176-8. PubMed ID: 3365862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
    Miller TT; Caldwell G; Kaye JJ; Arkin S; Burke S; Brill PW
    Pediatr Radiol; 1993; 23(7):523-4. PubMed ID: 8309753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
    Gallant T; Boyden MH; Gallant LA; Carley H; Freedman MH
    Am J Med; 1987 Dec; 83(6):1085-90. PubMed ID: 3503576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desferrioxamine-related ocular toxicity: a case report.
    Simon S; Athanasiov PA; Jain R; Raymond G; Gilhotra JS
    Indian J Ophthalmol; 2012 Jul; 60(4):315-7. PubMed ID: 22824603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of desferoxamine on retinal and visual function.
    Lu M; Hansen RM; Cunningham MJ; Eklund SE; Fulton AB
    Arch Ophthalmol; 2007 Nov; 125(11):1581-2. PubMed ID: 17998528
    [No Abstract]   [Full Text] [Related]  

  • 34. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.
    Wonke B; Hoffbrand AV; Aldouri M; Wickens D; Flynn D; Stearns M; Warner P
    Arch Dis Child; 1989 Jan; 64(1):77-82. PubMed ID: 2923478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodal imaging in a case of deferoxamine-induced maculopathy.
    Gelman R; Kiss S; Tsang SH
    Retin Cases Brief Rep; 2014; 8(4):306-9. PubMed ID: 25372534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M; Di Bella D; Pizzarelli G; Leonardi C; Sciuto C; Coco M; Di Gregorio F
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract]   [Full Text] [Related]  

  • 38. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
    Baath JS; Lam WC; Kirby M; Chun A
    Retina; 2008 Jun; 28(6):894-9. PubMed ID: 18536609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major.
    Christoforidis A; Perifanis V; Athanassiou-Metaxa M
    Br J Haematol; 2006 Oct; 135(2):271-2. PubMed ID: 16965387
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiomyopathy and pericardial effusion in a 7 year-old boy with beta-thalassaemia major, severe primary hypothyroidism and hypoparathyroidism due to iron overload.
    De Sanctis V; Govoni MR; Sprocati M; Marsella M; Conti E
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():181-4. PubMed ID: 19337175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.